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Members of the transforming growth factor b (TGF-b) family are implicated in the biology of several
cancers. Here we focus on malignancies of the brain and examine the TGFb and the bone
morphogenetic protein (BMP) signaling branches of the family. These pathways exhibit
context-dependent actions during tumorigenesis, acting either as tumor suppressors or as
pro-tumorigenic agents. In the brain, the TGF-bs associate with oncogenic development and progres-
sion to the more malignant state. Inversely, the BMPs suppress tumorigenic potential by acting as
agents that induce tumor cell differentiation. The latter has been best demonstrated in grade IV
astrocytomas, otherwise known as glioblastoma multiforme. We discuss how the actions of
TGF-bs and BMPs on cancer stem cells may explain their effects on tumor progression, and try to
highlight intricate mechanisms that may link tumor cell differentiation to invasion. The focus on
TGF-b and BMP and their actions in brain malignancies provides a rich territory for mechanistic
understanding of tumor heterogeneity and suggests ways for improved therapeutic intervention,
currently being addressed by clinical trials.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. TGF-b and BMP actions in cancer the family, leading to positive auto-regulatory loops that sustainThe largest family of developmental polypeptide growth factors
is the transforming growth factor b (TGF-b) family that includes
thirty-three human genes encoding for biologically important pro-
teins such as activins, bone morphogenetic proteins (BMPs) and
growth differentiation factors (GDFs), which control embryonic
development, organogenesis and adult organ homeostasis [1,2].
TGF-b was originally discovered as an inducer of oncogenic trans-
formation and today we appreciate its complex role in cancer pro-
gression, which is characterized by the parallel or sequential
involvement of many of its family members in the evolution of a
given cancer [3]. TGF-b members score prominently in other
human diseases, beyond cancer, because these factors are resident
in a dormant state in the extracellular environment of adult tissues
and their functions become activated every time tissues get
wounded or inﬂamed [4]. In addition, the pathogenic activation
of the TGF-bs leads to an imminent cascade of synthesis, secretion
and activation of the same and many of its sister growth factors ingrowth factor activity over time and contribute to disease progres-
sion [4]. Local tissue residence of TGF-b family members aims at
the maintenance of organ homeostasis; when tumor development
proceeds, cancer cells succeed in inactivating the function of the
TGF-b pathways by genetically altering some key molecules [5].
Induction of cytostasis and apoptosis by TGF-b family members
contributes to the homeostatic control, whereas the sustained
auto-inductive cycles of these cytokines contributes to their abun-
dant presence in all cancers and their subsequent contribution to
cancer cell dedifferentiation, neo-angiogenic stimulation and sup-
pression of immune surveillance by resident cells in the developing
cancer microenvironment [4,5].
The signaling pathways that mediate physiological and patho-
logical effects of the TGF-b family are highly conserved in all meta-
zoan organisms and involve the type II and type I receptors that
form heterotetrameric complexes on the cell surface and bind
the dimeric ligands, initiating signaling by the protein kinases of
the two receptor types (Table 1) [1,3]. Using a sequential mecha-
nism, ligand-bound type II receptor recruits and phosphorylates
the type I receptor, which then recruits and phosphorylates Smad
family proteins, the Smad1, Smad5 and Smad8 in the BMP
sub-family and the Smad2 and Smad3 in the TGF-b sub-family,
all ﬁve of which can pair with Smad4, a family member that is
Table 1
TGF-b family ligands and receptors.
Ligand Type I receptor Type II receptor
TGF-b1 TGFbRI/ALK5, ActRIA/ALK1 TGFbRII
TGF-b2 TGFbRI/ALK5, ActRIA/ALK1 TGFbRII
TGF-b3 TGFbRI/ALK5, ActRIA/ALK1 TGFbRII
ActivinbA ActRIB/ALK4 ActRIIA, ActRIIB
ActivinbB ActRIB/ALK4, ActRIC/ALK7 ActRIIA, ActRIIB
GDF1 ActRIB/ALK4, ActRIC/ALK7 ActRIIA, ActRIIB
GDF3 ActRIB/ALK4, ActRIC/ALK7 ActRIIA, ActRIIB
Nodal ActRIB/ALK4, ActRIC/ALK7 ActRIIA, ActRIIB
BMP3B/GDF10 ActRIB/ALK4 ActRIIA,
GDF11 TGFbRI/ALK5, ActRIB/ALK4 ActRIIA, ActRIIB
GDF8/myostatin TGFbRI/ALK5, ActRIB/ALK4 ActRIIB
GDF9a TGFbRI/ALK5, ActRIB/ALK4,
ActRIC/ALK7
ActRIIB
GDF9b BMPRII
BMP9 ActRIA/ALK1 ActRIIA, ActRIIB,
BMPRII
BMP10 ActRIA/ALK1 ActRIIA, ActRIIB,
BMPRII
BMP2 BMPRIA/ALK3, BMPRIB/ALK6 ActRIIA, ActRIIB,
BMPRII
BMP4 BMPRIA/ALK3, BMPRIB/ALK6 ActRIIA, ActRIIB,
BMPRII
GDF5 BMPRIA/ALK3, BMPRIB/ALK6 ActRIIA, ActRIIB,
BMPRII
GDF6 BMPRIA/ALK3, BMPRIB/ALK6 ActRIIA, ActRIIB,
BMPRII
GDF7 BMPRIA/ALK3, BMPRIB/ALK6 ActRIIA, ActRIIB,
BMPRII
BMP5 ActRIA/ALK2, BMPRIA/ALK3,
BMPRIB/ALK6
ActRIIA, ActRIIB,
BMPRII
BMP6 ActRIA/ALK2, BMPRIA/ALK3,
BMPRIB/ALK6
ActRIIA, ActRIIB,
BMPRII
BMP7 ActRIA/ALK2, BMPRIA/ALK3,
BMPRIB/ALK6
ActRIIA, ActRIIB,
BMPRII
BMP8A ActRIA/ALK2, BMPRIA/ALK3,
BMPRIB/ALK6
ActRIIA, ActRIIB,
BMPRII
BMP8B ActRIA/ALK2, BMPRIA/ALK3,
BMPRIB/ALK6
ActRIIA, ActRIIB,
BMPRII
GDF15 BMPRIA/ALK3 (?) ActRIIB (?)
BMP15 BMPRIB/ALK6 BMPRII
AMH ActRIA/ALK2, BMPRIA/ALK3 AMHRII
L. Caja et al. / FEBS Letters 589 (2015) 1588–1597 1589not phosphorylated by the type I receptor. The receptor complex
also recruits adaptor proteins and via post-translational modiﬁca-
tions, activates several signaling proteins that transmit biological
information in parallel to the receptor-phosphorylated Smads.
These signaling proteins are ubiquitin ligases, protein and lipid
kinases, and small GTPases [1,3]. The integrated signaling input
of all these proteins orchestrates a genomic response that is
tissue-speciﬁc and developmental stage- or pathogenic
state-speciﬁc and explains the impact TGF-bmembers have on var-
ious biological processes (Fig. 1) [1,3]. In the context of cancer,
physiological signaling mechanisms maintain their components
but seem to operate in a perturbed manner, sometimes due to
the absence or excessive abundance and overactivity of regulatory
proteins, and sometimes due to complete lack of speciﬁc key medi-
ators of the pathways, such as receptors, co-receptors or Smad pro-
teins. An interesting fact is the genetic inactivation of TGF-b family
signaling proteins that occurs in a tissue- or organ-speciﬁc manner.
In other words, whereas colorectal cancer preferentially mutates
the TGF-b type II receptor or Smad4 genes, and pancreatic cancer
almost universally mutates the Smad4 gene, breast cancer rarely
if ever, mutates genes in these pathways [4,5]. Brain malignancies
develop in a manner that strongly depends on the action of TGF-bs
and BMPs in the tumor microenvironment [6,7]. However, brain
tumor cells mutate genes of these pathways only with relatively
low frequency [8].
In this article, we discuss brain malignancies from the perspec-
tive of the TGF-b family, and due to space limitation we focus moreon the actions of the prototype members, TGF-bs and some of the
BMPs. We aim at comparing signaling mechanisms and coordina-
tion of cellular activities that contribute to the progression of the
disease. We highlight knowledge on cancer stem cells (CSCs) and
also discuss the problem of invasiveness in brain cancer. We ﬁnally
touch upon the prospect of therapy that is based on the basic
understanding of the function of TGF-b pathways.2. Brain malignancy and the TGF-b family
There are several types of central nervous system (CNS) malig-
nancies which are scaled between I and IV based on histologic fea-
tures of the tumor, according to the World Health Organization
(WHO). As a general rule, patients with grade II tumors survive
more than 5 years, patients with grade III tumors survive between
2 and 3 years; patients with grade IV tumors have the worst prog-
nosis, which also depends on the type of malignancy they are diag-
nosed with. For example, the grade IV brain tumor with the least
survival time after its diagnosis is glioblastoma multiforme
(GBM) with a median survival of 1 year, whereas cerebellar medul-
loblastoma, another grade IV brain tumor, if treated, can show a
5-year survival rate of 60–80% [9]. Gliomas are the most common
brain tumors, accounting for 80% of all CNS tumors; the most
aggressive form of gliomas is GBM. Here we will focus on those
brain tumors in which it has been reported that the TGF-b family
affects their initiation, growth and therapy response.
A hallmark feature of the association of cytokines like TGF-b
with the development of cancer is their detection and abundance
in the bloodstream of patients. For example, a correlation between
high TGF-b2 levels in the plasma of patients and their advanced
high-grade glioma and a poor prognosis has been reported [10].
Interestingly, the plasma levels of TGF-b2 were predicted to change
in patients receiving tamoxifen in their therapeutic cocktail, a
hypothesis proposed based on breast cancer studies [11].
However, in vivo studies in GBM patients could not reveal a good
correlation between TGF-b2 plasma levels and the patient response
to therapy, whereas in vitro, GBM cell lines cultured in the pres-
ence of tamoxifen did in fact present enhanced secretion of
TGF-b2. Similar to TGF-b2, studies on the prognostic value of
plasma levels of the mature and latent forms of TGF-b1 also failed
to reveal a clear correlation with prognostic signiﬁcance in GBM
patients treated with radiation [12]. Despite the results of these
earlier studies, more recently, expression of both TGF-b1 and
TGF-b2 was found to be higher in GBM compared to healthy brain
tissue, and the higher the expression of these two ligands, the
worse the prognosis for the patient [13]. Genome-wide expression
analyses in blood vessels after microdissection of the vascular cells
from GBM patient biopsies, identiﬁed TGF-b2 as a key mediator of
the dramatic neo-angiogenesis observed in the tumors of these
patients, and an overall enhanced Smad activity signature was
one of the key ﬁndings of this study [14]. It is worth noting that
detection of TGF-bs in biological ﬂuids has always been difﬁcult
and the technology and sensitivity of detection has clearly been
improved in the recent years. A member of the TGF-b family with
clear association with the progression of brain malignancy, and
undisputable prognostic value, is GDF15 [15]. Measurement of
GDF15 in the cerebrospinal ﬂuid provided more reliable results
when compared to the levels of GDF15 in the plasma, and clearly
patients with GBM and meningioma that scored high in the
GDF15 scale exhibited a shorter survival [15]. On the other hand,
BMP4 seems to be a predictor of good prognosis in gliomas [16].
The same has been established for BMP2 in GBMs and lower grade
gliomas [17]. These data already underscore that TGF-b and BMP
tend to have opposite roles in brain tumor development and
prognosis.
Fig. 1. Schematic representation of TGF-b and BMP signaling. Upon ligand binding to type II receptors, they form a heterotetrameric complex with the type I receptors, which
then phosphorylate the R-Smads (for the TGF-b arm Smad2/3, and for the BMP arm Smad1/5/8). R-Smads form a complex with the co-Smad, Smad4, and translocate to the
nucleus. TGF-b can also induce non-canonical pathways such as phospho-inositide 30 kinase (PI3K), mitogen activated protein kinase (MEK/ERK) and small GTPase (RhoA),
which will activate other transcription factors that act as co-factors to the Smad complexes. Together, the transcriptional co-factors and Smads can regulate the expression of
several genes, either inducing or repressing their expression. As depicted in the text, in brain tumors the TGF-b arm of the family mostly promotes cell self-renewal and
immune suppression, and the BMP arm of the family blocks self-renewal and enhances cell differentiation.
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brospinal ﬂuid are usually accompanied by in vitro studies of
human brain tumor cell lines and mouse models of brain malig-
nancy [6,7]. Interestingly, TGF-b2, although originally identiﬁed
in bovine bone, it was also molecularly cloned as a secreted factor
by GBMs [18], which spurred strong interest in the roles of the
TGF-b family in brain malignancy from the very early days of the
TGF-b ﬁeld.
In vitro analyses of the proliferative responses of normal astro-
cytes compared to GBM cells, explained that GBM cells retain
many responses to TGF-b, such as extracellular matrix synthesis
and pro-angiogenic factor secretion, whereas GBMs lack the
anti-proliferative response to TGF-b, partly due to the genetic loss
of the cell cycle inhibitor gene p15Ink4b [19]. The cell cycle inhibi-
tors p15Ink4b and p21Cip1 are major downstream effectors of
TGF-b-mediated cytostasis, and GBMs selectively express tran-
scription factors like FoxG1, that bypass the normal control of
these genes by the TGF-b receptor-activated Smad signaling [20].
Another mechanism that helps GBM cells bypass normal astrocyte
cell cycle control by TGF-b involves the phosphatase and tensin
homologue deleted on chromosome 19 (PTEN), which is frequently
inactivated in GBMs [21]. PTEN associates with Smad3 and down-
regulates its transcriptional activity, whereas loss of PTEN in GBMs
provides enhanced Smad3-dependent activity that renders TGF-b
pro-invasive and pro-tumorigenic. After this brief and selective
presentation of processes that link TGF-b function to malignant
phenotypes in the brain, we will proceed with a more systematic
analysis of the role of this family of cytokines in various key
anatomical and functional compartments of brain tumors.3. Brain tumor stem cells
Glioblastoma is the most aggressive type of CNS tumors;
despite several treatment strategies such as surgery, radiotherapy
and chemotherapy, the median survival is 1 year after diagnosis,
and this is thought to be due to the resistance and power of
CSCs. More than a decade ago the existence of CSCs in GBMs and
medulloblastoma was proven; such CSCs were identiﬁed as tumor
cells that express the CD133 protein on their surface, and trans-
plantation of as few as 100 CD133+ cells were sufﬁcient in recapit-
ulating the heterogeneity of the original tumor [22]. GBM CSCs
(G-CSCs) are multipotent, have the property of self-renewal and
are thought to be responsible for tumor maintenance, recurrence
and therapy resistance [22–25]. Several mouse models have pro-
vided evidence that normal neural stem and progenitor cells give
rise to malignant astrocytomas [26–28]. Similar to neural stem
cells (NSC), G-CSCs also give rise to more differentiated cells, the
bulk of the tumor, which is highly heterogenic and less tumori-
genic (Fig. 2). Interestingly, both NSCs and G-CSCs are controlled
by similar signaling pathways involved in neurogenesis and brain
formation, such as Notch, Sonic hedgehog (Shh), Wnt and the
TGF-b family [29].
3.1. TGF-b actions in brain CSCs
TGF-b is known to have cytostatic effects inducing the expres-
sion of p21Cip1 in epithelial cells as mentioned above; however,
in both neuroepithelial and glioblastoma cells, the levels of the
transcription factor FoxG1 are higher, causing this protein to
Fig. 2. Opposing actions of TGF-b and BMP signaling in glioblastoma multiforme cancer stem cells. A brain tumor made of its heterogenous differentiated cells (shown in pink
and green) and their associated tumor microenvironment is schematically drawn. CSCs (yellow) produce TGF-b and Gremlin in order to maintain their self-renewal; TGF-b
promotes immunosuppression in the tumor microenvironment. At the same time, the immune cells inﬁltrating the tumor produce TGF-b that will have an autocrine effect
and enhance self-renewal of CSCs and migration of cells in the main tumor mass. TGF-b derived from CSCs induces angiogenesis in the surrounding endothelial cells.
Simultaneously, endothelial cells also produce TGF-b that drives CSC to differentiate towards pericytes. Exogenous BMPs or NPC-derived BMPs act on the CSCs promoting
their differentiation towards several lineages depending on the brain tumor type. Finally, tumor cell migration can be promoted by TGF-b, BMPs and several EMT-TFs.
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promote p21Cip1 expression in response to TGF-b [20]. This mech-
anism explains how GBMs can resist to cytostatic TGF-b, and
switch their response to this cytokine, thus promoting cell prolifer-
ation. A clear correlation between poor survival and high levels of
phospho-Smad2 has been demonstrated; high levels of proliferat-
ing cells correlated with high levels of phospho-Smad2 in GBM
patients, indicating a positive role of TGF-b in GBM cell prolifera-
tion [30]. According to this work, TGF-b promotes proliferation of
glioma cells by inducing the expression of platelet-derived growth
factor (PDGF)-BB in a Smad2/3-dependent manner. Interestingly,
another report proposed that transcription factor Olig1 is also
involved in PDGF-BB induction in response to TGF-b, whereas the
transcriptional regulator human homologue of Maid (HHM) could
counteract the positive effect of Olig1 on the transcriptional regu-
lation of PDGF-BB by Smad2/3 [31]. In addition, TGF-b can promote
the growth of glioma cells and inhibit apoptosis by inducing the
expression of another TGF-b family member, Nodal; interestingly,
Nodal expression in grade IV glioma correlates to the invasive
potential of tumor cells in an in vivo model as well as in a patient
cohort [32,33]. TGF-b1 can also induce the expression of TGF-b2 in
GBM cell lines in a CREB1- and Smad2/3-dependent manner
[13,34], and knockdown of CREB1 results in fewer tumors and
longer survival. Another pathway through which TGF-b promotes
the aggressiveness of glioma is by sustained activation of nuclear
factor of j light polypeptide gene enhancer in B-cells (NF-jB),
via upregulation of the micro-RNA miR-182, which suppresses
the cylindromatosis protein Cyld, an established negative regulator
of NF-jB signaling [35].
Autocrine production of TGF-b is necessary for G-CSCs to main-
tain their stemness, which acts via different downstream pathways
(Fig. 2). TGF-b up-regulates the expression of the stem cell tran-
scription factor Sox2 through its sibling, Sox4, in a
Smad2/3-dependent manner; in agreement, inhibition of TGF-breceptors results in down-regulation of the expression of Sox4
and Sox2, and decreased self-renewal capacity as well as
down-regulation of stem cell markers, such as CD133, nestin and
Musashi [36]. TGF-b, in a Smad2/3-dependent manner, also
induces the expression of the cytokine leukemia inhibitory factor
(LIF) in order to enhance G-CSC stemness, and treatment of
G-CSCs with TGF-b or LIF in vitro, increases their self-renewal
capacity and their tumor-initiating potential in vivo [37]. TGF-b
increases the numbers of G-CSCs that are positive for the surface
protein CD44 and also induces the expression of the transcriptional
regulators Id1 and Id3; in contrast, inhibition of TGF-b receptors in
G-CSCs reduces their self-renewal capacity by diminishing the
G-CSC subpopulation of CD44high/Id1high cells, which results in a
decrease of their tumor-initiating capacity and oncogenic potential
[38]. Interestingly, Id1, Id3, LIF, Sox2 and Sox4 are all necessary to
maintain the CD44high population, indicating that all these molec-
ular pathways are interconnected. However, not all G-CSCs
respond potently to TGF-b and this can be explained by the genetic
background of GBMs in different patients. For example, a small
percentage of GBM patients show ampliﬁcation of the USP15 (ubiq-
uitin speciﬁc peptidase 15) gene, coding for a deubiquitinating
enzyme, which deubiquitinates and stabilizes the TGF-b type I
receptor, leading to enhanced TGF-b activity in those tumors and
promoting their tumor-initiating capacities [39]. Obviously, GBM
patients with low or no activity of USP15 would suffer from rela-
tive resistance to TGF-b.
3.2. BMP actions in brain CSCs
In contrast to the positive effects that TGF-b exerts on G-CSC
stemness, BMPs have been proven to have opposite functions
(Fig. 2). First, it was published that treatment with BMP4 decreases
the percentage of CD133+ cells in G-CSCs, and promotes their dif-
ferentiation mainly towards astrocytes, and to a lesser extent
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could also reduce GBM cell proliferation. In agreement with these
results, a BMP7 variant could also reduce G-CSC proliferation and
induce their differentiation towards astrocytes and neurons both
in vitro and in vivo [41]. We demonstrated that in order for
BMP7 to promote GBM differentiation, up-regulation of the tran-
scription factor Snail is required, and the sole overexpression of
Snail could mimic many of the effects of BMP7 treatment both
in vitro and in vivo [42]. All these data indicate that BMPs act as
tumor suppressors in GBM. Moreover, in a subset of GBM patients,
the type I receptor gene BMPR1B is hypermethylated by the
Polycomb group histone methyltransferase EZH2, rendering these
tumors resistant to BMP-induced differentiation [43]. In agreement
with this mechanism, another subunit of the Polycomb group com-
plex, the stem cell factor BMI1 has been shown to suppress genes
like the transcription factor ATF3 (activating transcription factor 3),
which limits GBM cell responsiveness to BMP signaling and
enhances GBM responsiveness to TGF-b signaling [44]. GBMs that
inactivate the function of BMI then switch their responsiveness
and become hypersensitive to the differentiating potential of
BMP, while losing their sensitivity to TGF-b. The speciﬁc mecha-
nisms by which ATF3 would protect GBMs from acquiring
stem-like and self-renewing features may involve the transcrip-
tional activity of ATF3 complexes with other components of the
activating protein 1 (AP-1) family of transcription factors, and
requires further deeper understanding [44]. Another mechanism
by which G-CSCs bypass BMP-induced differentiation is the high
expression levels of the extracellular BMP antagonist Gremlin
[45]. A G-CSC sub-population expresses higher levels of Gremlin
compared to non-G-CSC tumor cells, and overexpression of
Gremlin in the non-G-CSC cells was sufﬁcient to shift them
towards a G-CSC phenotype resulting in enhancement of their
tumor-initiating properties (Fig. 2). In contrast to the previous
results, it has also been described that BMP2 can promote GBM
proliferation, migration, enhanced self-renewal of G-CSCs in vitro
and enhanced tumor formation in vivo [46]. Sensitivity of the
GBMs to BMP2 is further secured due to downregulation of
miR-656, which targets the type I receptor BMPR1A and when
highly expressed, miR-656 can impair BMP2 effects [46].
4. TGF-b and BMP actions in other brain tumors
Medulloblastoma (MB) is the most common malignant pedi-
atric brain tumor, and according to histopathological characteris-
tics, ﬁve subgroups of MB are currently classiﬁed by WHO;
however, according to classiﬁcation based on MB gene expression
proﬁles, only four subgroups can be recognized, including genes
that exhibit alterations in the (1) Wnt pathway, (2) Shh pathway,
(3) Myc signaling and (4) undeﬁned genetic processes [47].
Activation of Shh promotes proliferation in MBs and BMP2 can
block Shh-induced proliferation by upregulating the expression
of the zinc ﬁnger transcription factor TIEG1 (TGF-b
immediate-early gene 1), which can repress N-Myc transcription
[48]. BMP2 can also promote differentiation of cerebellar granular
neuronal precursors (CGNPs) towards neurons [48]. Another mech-
anism through which BMP2 and BMP4 inhibit CGNP proliferation
and induce their differentiation is by rapid proteasome-mediated
degradation of Atoh1/Math1, a bHLH transcription factor required
for cerebellar development [49]. BMP2 has also been described to
induce apoptosis in MBs [50]. In contrast to the Shh subgroup of
MB, in the Myc subgroup, it has been described that Myc promotes
BMP7 expression which is required for MB cell proliferation and
survival [51]. A large screen of MB patients belonging to the Myc
group showed that 20% of the cases were enriched in expression
of TGF-b pathway-related genes; in addition, the type II activinreceptors ACVR2A and ACVR2B and the TGF-b type I receptor
TGFBR1 were highly ampliﬁed, which suggested possible new ther-
apeutic targets in this subgroup of MB, characterized by its very
poor prognosis [52]. In another report, opposing results were
described, showing that patient samples with positive nuclear
staining of Smad3 correlated with a survival advantage in these
patients [53]; however, in this study, the patient subgroup 3
(Myc) was under-represented, which might explain the discrep-
ancy between the last two studies.
Diffusive high-grade gliomas (HGGs) that develop during child-
hood have a very poor survival: when the tumors arise in the cere-
bellar cortex, the 2-year survival chance of HGG patients is 30%;
when the tumors arise in the brain-stem they are called diffuse
intrinsic pontine gliomas (DIPGs) and their 2-year survival chance
is less than 10% [54]. High grade tumors share similar histopathol-
ogy and gene expression subgroups between adult glioblastoma
and childhood HGGs are also similar. However, recent publications
have shed light to the more rare tumors of children as being unique
in terms of the molecular process that drives their evolution,
depending on the genetic mutations acquired, the anatomical
regions were tumors form, and the age group. Thus, recent evi-
dence showed that the BMP type I receptor known as activin recep-
tor type I (ACVR1 or activin receptor-like kinase 2 (ALK2)) is
mutated in 24% of DIPG patients but not in paediatric NBS-HGGs.
ACVR1-mutant DPIGs occur earlier in age, have a longer survival
and are more frequent in females. The mutations identiﬁed are
p.Arg206His, p.Gly328Glu and p.Gly356Asp, located within the ser-
ine/threonine kinase domain or the glycine–serine (GS)
rich-domain of this type I receptor kinase, which is expected to
shift the kinase to an active conformation, and results in an
increased phosphorylation of Smad1/5/8 in the studied tumors.
The same ACVR1/ALK2 mutations found in DIPG are also found in
patients with the syndrome ﬁbrodysplasia ossiﬁcans progressiva
(FOP); however, the FOP patients are not predisposed to cancer,
which may reﬂect that ACVR1 mutations are not related to
tumor-initiating capacity in DIPG, but rather give an advantage
to tumor cells when mutations in different pathways coexist with
the ACVR1 mutations [55–58]. Patients with mutation in the his-
tone H3 gene (H3F3A) exhibited phosphorylated levels of
Smad1/5/8 even though they had wild-type ACVR1, suggesting
additional ways of BMP activation in DIPG [57]. However, further
studies are needed to validate whether ACVR1 can be a useful ther-
apeutic target in DIPG, and to understand its role in tumorigenesis.
Furthermore, in pediatric HGG precursors, it has been described
that oxygen levels modulate the BMP2 response: BMP2 induces
astroglial differentiation, but hypoxia can block this effect; hypoxia
can also attenuate the anti-proliferative effects of BMP2.
Interestingly, BMP2 can downregulate hypoxia-inducible factor a
(HIFa) under hypoxic conditions in paediatric HGG but not in nor-
mal subventricular cells [59]. Finally, the effects of BMPs in oligo-
dendroglioma propagating cells were recently characterized,
whereby BMPs decreased cell proliferation, depleted the CD133+
population, and promoted astrocytic differentiation, probably by
cytoplasmic sequestration of Olig1 and Olig2 by their inhibitory
partners, Id2 and Id4 [60].
Overall, the majority of published work indicates that BMP
pathways play pro-differentiation and anti-proliferative roles in
most brain tumors, except in DIPGs; in contrast, TGF-b mostly
plays pro-tumorigenic roles and promotes stemness and
self-renewal (Fig. 2).
5. Brain tumor invasiveness
The invasive nature of brain tumors plays an important role in
the ineffectiveness of surgery and is one of the causes behind their
L. Caja et al. / FEBS Letters 589 (2015) 1588–1597 1593poor prognosis and relapse. Moreover, some anti-angiogenic
treatments can unfortunately enhance glioma invasiveness [61].
The pattern of glioma cell migration follows the pattern of glial pro-
genitor cells during normal brain development, and in both cases it
is controlled by the local microenvironment. Microglia has been
proven to produce TGF-b that in turn promotes cell proliferation
and migration in GBM cells [62]. The integrin-b8 is known to acti-
vate the latent form of TGF-b1 in neural stem cells and it is also
important to regulate the invasiveness of GBM-perivascular tumor
cells [63,64]. TGF-b2 promotes glioma cell migration by enhancing
matrix metalloprotease 2 (MMP2) expression and its activity, as
well as by inducing the expression of integrin-avb3 [65,66].
Glioblastomas have been divided in three main subgroups
according to their molecular proﬁle, the proneural (tumors express
genes typical of neural progenitor cells), classical (they express
genes related to proliferation and receptor tyrosine kinase activa-
tion), or mesenchymal (they express genes related to mesenchy-
mal tissues) [67]. GBMs of the mesenchymal subgroup have
worse prognosis in comparison with proneural tumors [68].
TGF-b is known to induce an epithelial to mesenchymal transition
(EMT) in epithelial cancers giving rise to more motile and invasive
cells, which have acquired mesenchymal characteristics both at the
molecular and morphological level [69]. TGF-b regulates a network
of embryonic transcription factors in order to induce EMT: Snail,
Slug, Twist, ZEB1, and ZEB2, known as EMT-Transcription Factors
(EMT-TFs). The chromatin factor high mobility group A2
(HMGA2) is an immediate-early gene of TGF-b signaling and can
induce expression of Snail and Twist, whereas it binds to Snail
and together repress target genes like the epithelial E-cadherin
[69]. It was recently shown that TGF-b can also promote an equiv-
alent mesenchymal differentiation in GBM and this
trans-differentiation is associated with increased invasion both
in vitro and in vivo and depends on the induced expression of
ZEB1 [70]. TGF-b can switch cells from the proneural to a mes-
enchymal subtype. BMP7 has also been shown to induce GBM cell
migration in a Snail-dependent manner, enhancing the expression
of mesenchymal markers such as ﬁbronectin [42]. Another factor
that can promote this shift from the proneural to the mesenchymal
phenotype is ionizing radiation, involving the transcriptional activ-
ity of Stat3 and CREB in Olig2+ progenitor cells [71]. Whether
TGF-b or EMT-TFs are also involved in the radiation-induced shift
of neuroepithelial to mesenchymal cells requires further studies.
In agreement with the fact the both TGF-b and BMP can induce
GBM migration through enhanced expression of EMT-TFs (Fig. 2),
several reports have provided links between different EMT-TFs
and glioma cell invasion. Nuclear staining of Slug and Twist1 has
been observed in mesenchymal tumor areas of gliosarcomas but
not in glial areas [72]. Slug has been associated with enhanced
migration, stemness and tumorigenesis in glioma cells [73]. High
levels of Twist1 expression are associated with the highest grade
of glioma [74]. Twist1 overexpression is sufﬁcient to increase
in vitro migration and in vivo invasion; Twist1 can enhance the
expression of Slug, the matrix metalloprotease MMP2 and other
genes involved in invasion [75]. Snail was ﬁrst reported to be nec-
essary for GBM cell migration and proliferation in vitro [76,77] and
in vivo [42]; later it was demonstrated that its expression is
enhanced concomitant with a glial to mesenchymal transition after
irradiation in glioma patients [78]. In vitro experiments showed
that Snail expression is necessary for irradiation to induce a mes-
enchymal gene proﬁle and to promote migration [78]. One mech-
anism for irradiation-induced Snail expression is through release
of TGF-b1 by ﬁbroblasts and macrophages resident in the tumor
microenvironment [78]. Migration of GBMs can be promoted by
Snail, which can repress the miR-128, which in turn represses
the transcription factor SP1; the end result is enhanced expressionof SP1 which cooperates with Snail in regulating the expression of
pro-invasive metalloproteases [76].
ZEB2 is highly expressed in GBM tumor samples compared to
normal brain tissues, and in vitro experiments show ZEB2 as being
responsible for GBM cell survival and invasion, since silencing of
ZEB2 is sufﬁcient to promote apoptosis and to block cell migration
[79]. ZEB1 expression correlates with poorer GBM patient survival
and poor response to temozolomide (TMZ), the adjuvant
chemotherapy included in standard GBM care [79]. This can be
explained because ZEB1 represses the miR-200, which in turn is
responsible to suppress c-MYB that upregulates the expression of
O-6-methylguanine DNA methyltransferase (MGMT), the
chromatin-remodeling protein responsible for TMZ resistance.
Moreover, ZEB1 is highly expressed in the edges of GBM tumors,
promoting GBM cell invasion by repressing miR-200, which blocks
the expression of the guidance receptor ROBO1 responsible for
tumor invasion [79]. Finally, the transcriptional loop
ZEB1-miR-200 also regulates G-CSC stemness, controlling the
expression of the stem cell factors CD133, Olig2 and Sox2 [80].
The chromatin modifying protein HMGA2 mentioned earlier as a
strong promoter of EMT and metastasis [69] has also been associ-
ated with the poor prognosis of gliomas [81], which could be
explained by its capacity to promote Sox2 expression and therefore
a G-CSC population with tumor-initiating capacity [82].
6. Roles of TGF-b and BMP in the tumor microenvironment
In the last decade, the importance of the tumor microenviron-
ment in tumor progression and its role as the niche for CSCs has
surfaced. G-CSCs have been described to reside near vascularized
areas within the tumor [83]. Not only do G-CSCs take advantage
of the existing vasculature, but they also induce angiogenesis
[84], plus they can generate vascular pericytes in order to support
the structure and function of the vasculature; most of GBM peri-
cytes are derived from neoplastic cells (Fig. 2). In part this
trans-differentiation is driven by TGF-b produced by endothelial
cells (ECs) acting on the G-CSCs [85]. At the same time, TGF-b
secreted from GBM cells can affect ECs and promote angiogenesis
by increasing the expression of the insulin-like growth
factor-binding protein 7 (IGFBP7) [86]. Similarly, EC-secreted
TGF-b induces the expression of the mesenchymal cadherin-11 in
nearby GBM cells, enhancing their invasive potential, a process
that mimics embryonic exit and migration of neuroepithelial cells
from the ventricular zone [87].
Glioma-associated microglia and macrophages (GAMs) can con-
tribute up to 30% of the mass of a brain tumor. G-CSCs recruit
GAMs into the tumor and promote their shift towards M2 macro-
phages (Fig. 2). TGF-b is known to be able to promote the M2 shift
in other tumors, but in glioma it has not been properly proven. The
tumor-promoting M2 macrophages are characterized by having
diminished capacity to induce an anti-tumor T cell response, are
able to mediate immune suppression and produce several factors
that stimulate glioma growth, neovascularization and invasiveness
[88]. On one hand, tumor-derived TGF-b can suppress the activa-
tion and proliferation of microglia [89]. On the other hand, micro-
glia ablation results in reduction of glioma size and improved
survival [90] as well as reduced migration [91], indicating the
importance of microglial cells in glioma progression. One of the
mechanisms through which microglia exerts its pro-invasive func-
tions is by secreting TGF-b [62]. Moreover, tumor-associated
microglia/macrophages enhance G-CSC invasion through their pro-
duction of TGF-b1 that enhances MMP9 expression in CD133+ GBM
cells [92]. Another immune cell type present in the microenviron-
ment of gliomas is myeloid-derived suppressor cells (MDSCs),
which is a heterogeneous population of activated immature
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granulocytes, which can cause immune suppression (Fig. 2).
MDSCs among other cytokines secrete TGF-b1 which might con-
tribute to their immunosuppressive effects [93].
TGF-b has been described to promote recruitment and/or
expansion of regulatory T cells (Treg) in gliomas, as systemic
administration of the anti-TGF-b1 mAb, 1D11, results in a
decreased inﬁltration of Treg in these tumors [94]. In high-grade
glioma, an abundant population of IL-17+ Tregs has been described
and found responsible for suppressing CD8+ T cell proliferation in a
TGF-b-dependent manner [95] (Fig. 2). Moreover, another mecha-
nism through which TGF-b exerts its immunosuppressive role is
by downregulating the expression of the activating receptor
NKG2D (natural-killer group 2, member D) in CD8+ T cells and in
natural killer (NK) cells; silencing of TGF-b1 and TGF-b2 in glioma
cells promotes their recognition by CD8+ T and NK cells [96,97].
Finally, TGF-b silencing, as mentioned in the previous section,
resulted in loss of migratory and invasive capacities by glioma cells
[97]. TGF-b1 and TGF-b2, by reducing the expression of the adhe-
sion proteins ICAM-1 (intercellular adhesion molecule 1) and
VCAM-1 (vascular cell adhesion molecule 1) in GBM-associated
ECs, can reduce T cell transmigration, suggesting that TGF-b block-
ade would result in improved intratumoral T cell inﬁltration and
better response to immunotherapies [98]. In a medulloblastoma
mouse model, it has been observed that blocking the TGF-b path-
way in T cells (both CD4+ and CD8+ populations) results in slower
progression of the disease, reduced Treg inﬁltration and promoted
CD8+ T cell differentiation into CD8+ cytotoxic T lymphocytes con-
ferring antitumor immunity [99]. All together the evidence indi-
cates that TGF-b in glioma and other brain tumors has a potent
immunosuppressive role and blockade of the TGF-b pathway will
not only affect the G-CSC population and tumor cell invasive
capacity, but will also improve the capacity of the immune system
to play its anti-tumor activities.
Finally, glioblastoma cells can also attract and interact with
neural precursor cells (NPCs) [100]. NPCs can secrete several
molecules, among them BMP7 which can promote G-CSC differen-
tiation and play a tumor suppressor role [101] (Fig. 2); this
anti-tumor response is much more potent in young compared to
old mice.
7. Therapeutic perspectives
7.1. BMP-based therapy
As introduced earlier, the fact that GBM accounts for 52% of pri-
mary brain malignancies [102], and its characteristic poor survival
(12–15 months with multimodal therapy), poor treatability, fre-
quent relapse and acquired chemoresistance to temozolomide
[103], make the prospect of new therapies against GBM a task of
imminent importance. Moreover, GBM has a poor metastatic out-
spread but signiﬁcant inﬁltration into the brain and spinal chord,
factors that hinder its surgical resection. All these features con-
tribute to deﬁne GBM as a hard to treat and difﬁcult to cure malig-
nancy, based on the current chemotherapeutic, radiotherapeutic
and surgical resection approaches. It is therefore considered
important to elucidate new effective strategies for GBM treatment,
which can lead to its complete regression. It has been addressed
how future strategies might encompass different routes: targeting
the vascular niche or the therapeutic resistance of G-CSCs, blocking
G-CSCs via their speciﬁc markers (CD133 or L1CAM (L1 cell adhe-
sion molecule)), modulating signaling pathways that are abnor-
mally regulated in the G-CSC population -such as Notch, BMP,
TGF-b, STAT3 or Wnt- targeting transcription factors or miRNAs
that are differentially expressed in or affect the G-CSC population
by forcing cell differentiation [103].In this article, we have explained how the misregulation of
TGF-b and BMP pathways can contribute to GBM progression,
either by inﬂuencing invasiveness and the angiogenic process, or
by acting on the stem cell niche and the stromal cell pool. Thus,
recent studies have focused on understanding how these pathways
can be modulated in order to increase the effectiveness of GBM
treatment. For example, BMP2 could sensitize G-CSCs to temozolo-
mide by blocking the HIF1a/MGMT pathway, involved in chemore-
sistance acquisition [104]. In particular, once highly tumorigenic
and core tumor layer-derived G-CSCs are pretreated with BMP2,
they become more sensitive to the cytotoxic effect of TMZ, with
consequent depletion in the stem niche and induction of
differentiation of live remaining G-CSCs. This study also
elucidated how BMP2/TMZ can downregulate HIF1a and the
HIF1a-dependent MGMT expression, thus reducing GBM chemore-
sistance [104]. Furthermore, it has recently been reported how
BMP4-engineered vaccinia viral particles induce G-CSC growth
inhibition, loss of stemness and acquisition of differentiation fea-
tures in vitro. BMP4-producing vaccinia viruses were then deliv-
ered intracranially in an orthotopic mouse model of GBM, thus
leading to an improved tumor regression, lower tumor burden
and better survival in vivo [105]. In addition, the importance of
blocking the BMP9 pathway during angiogenesis via the use of
the small molecule kinase inhibitor K02288 binding to the
endothelial type I receptor ALK1 has been deﬁned [106]. This inhi-
bitor decreased both Smad- and Notch-dependent responses, caus-
ing hypersprouting of the vessels and dysfunctional angiogenesis
in vitro, whichmight be of interest considering the ﬂorid neoangio-
genesis in GBM [106]. Intriguingly, a biodegradable device that
provides controlled release of bioactive BMP7 in vitro has been
described, where BMP7 was encapsulated in a heparin core and
surrounded by a shield of biodegradable polyester matrix [107].
This nano-system was able to release bioactive BMP7 in a con-
trolled fashion for 2 months inhibiting neurosphere formation
and cell proliferation in vitro [107].
7.2. TGF-b-based therapy
Targeting also the TGF-b pathway in GBM might be a promising
strategy of treatment. As an example, the inhibition of TGF-b2 -the
most abundant TGF-b isoform in GBM- with the antisense oligonu-
cleotide AP12009 was associated with prolonged survival in three
phase I/II studies on patients with recurrent or refractory
high-grade gliomas and complete tumor remission in two patients
[108]. Additionally, the TGF-bRI kinase inhibitor LY2109761 was
found to decrease clonogenicity, enhance apoptosis and promote
radiosensitivity in GBM cell lines, while after intracranial adminis-
tration it was associated with reduced tumor growth, invasion and
neoangiogenesis and prolonged survival in a GMB xenograft model
[109]. The positive correlation between an active TGF-b signaling
and GBM radioresistance was pointed out also in another study,
which clariﬁes how inhibiting the TGF-b pathway with the
TGF-bRI kinase inhibitor LY364947 or a pan-TGF-b neutralizing
antibody in vitro, can sensitize GBM cells to ionizing radiation
due to reduction of the DNA damage response [110]. This study
also demonstrated how TGF-b inhibition in conjunction with radi-
ation was able to decrease neurosphere forming ability in vitro
[110]. A study of dose escalation of the TGF-bRI kinase inhibitor
LY2157299 monohydrate in patients has lately been reported,
which was assessed to be safe – without any signs of cardiac tox-
icity – and effective for patients, with a partial or complete
response in 21% of the cohort members [111].
Interestingly, TGF-b can also affect other signaling pathways,
such as vascular endothelial growth factor (VEGF), in order to pro-
mote acquired chemoresistance. For example, the use of VEGF inhi-
bitors can paradoxically induce TGF-b signaling, which leads to
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CXCL12. This promotes GBM invasiveness and suggests that block-
ing the TGF-b pathway, might be a promising adjuvant solution to
current radiotherapy regiments [112].
All examples of therapy are derived from studies in GBM, as
therapeutic approaches of other types of brain malignancy have
not yet been based on the manipulation of the TGF-b and BMP
pathways. The new examples of DIPG suggest that new focus
should be addressed to the inhibition of the ACVR1/ALK2 receptor,
an area that will most certainly thrive in the near future. Taken
together, TGF-b and BMPs can be considered potentially interesting
pathways to modulate in order to enhance the efﬁciency of current
chemotherapeutic and radiotherapeutic approaches in malignan-
cies of the brain.
8. Conclusions and perspectives
In conclusion, TGF-b family members are important players in
brain tumor progression. TGF-b1 and TGF-b2 are key factors that
promote CSC self-renewal, tumor cell migration and that repress
the immune system. In contrast, BMPs in most brain tumors pro-
mote CSC differentiation and block proliferation. However, BMPs
can also enhance tumor cell migration, and their role in the brain
tumor immune response is not well studied. TGF-b and BMP path-
ways are well studied, however, their use as either therapeutic tar-
gets or agents respectively have still not proven as effective as
expected. This is probably due to the signaling complexity of the
TGF-b family. The urgent need for combinatorial therapies to
improve patient survival and block tumor recurrence suggests that
anti-TGF-b and pro-BMP agents can be used in combination with
other drugs to enhance the efﬁcacy of therapy in malignancies of
the brain.
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